The Food and Drug Administration approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. “This decision, which was issued 55 days after filing, marks the third approval under the new Commissioner’s National Priority Voucher pilot program,” the regulator stated. The FDA granted the approval to Johnson & Johnson’s Janssen Biotech.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
- Johnson & Johnson price target raised to $250 from $225 at JPMorgan
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Johnson & Johnson Stock Forecast: Trending Analyst Sees Limited Upside
- Johnson & Johnson says FDA grants Fast Track designation to nipocalimab